Edgestream Partners L.P. Invests $1.01 Million in DexCom, Inc. (NASDAQ:DXCM)

Edgestream Partners L.P. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,041 shares of the medical device company’s stock, valued at approximately $1,014,000.

Several other hedge funds have also added to or reduced their stakes in the business. Versant Capital Management Inc bought a new position in shares of DexCom in the fourth quarter valued at about $25,000. Private Trust Co. NA grew its stake in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in DexCom in the 4th quarter valued at about $38,000. SBI Securities Co. Ltd. acquired a new position in DexCom in the 4th quarter valued at about $49,000. Finally, Midwest Capital Advisors LLC bought a new stake in shares of DexCom during the fourth quarter worth approximately $54,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DXCM shares. Citigroup increased their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group increased their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research report on Saturday. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

Insider Transactions at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 7,000 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now owns 135,482 shares of the company’s stock, valued at approximately $10,002,636.06. The trade was a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,083 shares of company stock valued at $3,826,604. 0.30% of the stock is currently owned by insiders.

DexCom Stock Down 0.7 %

NASDAQ DXCM opened at $70.26 on Wednesday. The business has a fifty day moving average price of $84.53 and a two-hundred day moving average price of $76.98. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock has a market capitalization of $27.46 billion, a PE ratio of 49.13, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.